Valerie Velho Denz, MD
Pulmonary Disease · West Burlington, IANPI 1609893510
Payments from drug & device makers
Across 23 payments — averaging $20.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$92
- Boehringer Ingelheim$80
- Merck$53
- GSK$47
- Grifols USA, LLC$39
- Genentech USA, Inc.$26
- plus $131 from 7 others
What the payments were for
- Food & beverage$42190%
- Education$4710%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 1 | $92 |
| Boehringer Ingelheim | 3 | $80 |
| Merck | 3 | $53 |
| GSK | 3 | $47 |
| Grifols USA, LLC | 3 | $39 |
| Genentech USA, Inc. | 2 | $26 |
| AstraZeneca | 2 | $23 |
| Mylan Specialty L.p. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $21 |
| Electromed, Inc. | 1 | $18 |
| Resmed Corp | 1 | $17 |
| Johnson & Johnson | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
How this compares
$468 in reported general payments places this provider in the 40th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 37 | $453,462 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 423 | $336,273 |
| Dupixent PenDupilumab | 20 | $79,635 |
| NucalaMepolizumab | 14 | $51,791 |
| Spiriva RespimatTiotropium Bromide | 72 | $46,916 |
| Incruse ElliptaUmeclidinium Bromide | 95 | $35,156 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 58 | $30,355 |
| Breo ElliptaFluticasone/Vilanterol | 49 | $24,279 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $23,056 |
| SymbicortBudesonide/Formoterol Fumarate | 71 | $20,185 |
| Roflumilast | 162 | $17,054 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 42 | $16,898 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $12,831 |
| Spiriva HandihalerTiotropium Bromide | 19 | $10,818 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 23 | $10,725 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $80 | $523,933146 claims |
| GSKTrelegy Ellipta, Nucala, Incruse Ellipta, Anoro Ellipta, Breo Ellipta | $47 | $477,854639 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $23 | $60,139145 claims |
| Johnson & JohnsonXarelto | $17 | $6,16412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in West Burlington
- John ScottWest Des Moines$2.1M
- Alejandro ComellasIowa City$1.6M
- Matthew TrumpWest Des Moines$969K
- Bryan KrajicekCouncil Bluffs$688K
- Douglas HornickIowa City$561K
- Nabeel HamzehIowa City$424K
- Ryan BrimeyerWest Des Moines$410K
- Sumit MukherjeeCouncil Bluffs$264K
- John SouthardCouncil Bluffs$245K
- Alicia GerkeIowa City$240K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.